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Abstract
Introduction: Migraine has a considerable social, economic, physical and emotional burden but remains underdiagnosed
and undertreated. A specific migraine screening tool could help remove barriers to health care and be an attractive
instrument for epidemiological studies. The objective of this work was to assess the validity of an extended French
version of ID MigraineTM as a migraine-screening tool.
Methods: Sixty-seven subjects from the NESCaV study (2010–2012) completed the migraine screen and were diagnosed
by a neurologist specializing in headache medicine using the International Classification of Headache Disorders, 2nd
edition criteria (gold standard). Agreement between the two diagnoses was evaluated by Cohen kappa coefficient (k).
Sensitivity, specificity and predictive values of the migraine screen were calculated.
Results: Migraine was diagnosed in 21 (31.3%) of the 67 subjects according to the screening tool and in 24 (35.8%) by the
neurologist (k¼ 0.90). The prevalence of migraine was unrelated to age, gender, education and perception of financial
resources. Sensitivity and specificity of the screen were 87.5% and 100%, respectively. The screen prevalence of migraine
with aura was 10.4% (sensitivity and specificity: 83.3% and 96.7%, respectively).
Conclusion: The extended French version of ID MigraineTM (ef-ID Migraine) is a validated tool to screen migraine in
French-speaking countries.
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Introduction
Migraine is a highly prevalent and disabling neuro-
logical condition interfering in everyday life with
employment, household work, and social activities.
About 15% of European adults (8% of men and 17%
of women) suﬀer from migraine. The cost of migraine
in Europe is estimated at E27 billion/year including
direct and indirect costs due to the high prevalence
of the disorder (1). About a quarter of adult migraine
suﬀerers experience migraine with aura (MA). MA is
characterized by transient neurological symptoms,
classically scintillating scotoma, occurring before or at
the beginning of the headache (2). The 12-month preva-
lence of MA across studies is 4.4% (range: 1.2%–5.8%)
(3). Migraines with and without aura remain under-
diagnosed and undertreated throughout the world
(4,5). A valid screening tool implemented through a
brief self-administered questionnaire could help
remove barriers to health care and hence improve
treatment (5). Moreover, a self-administered question-
naire is an attractive instrument for epidemiological
studies, being inexpensive and relatively easy to use
(6). The diagnosis of migraine is based on a combin-
ation of symptoms (headache characteristics and asso-
ciated symptoms like photophobia or nausea) that are
deﬁned by the International Classiﬁcation of Headache
Disorders, 2nd edition (ICHD-II) (7) and easily
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captured by questionnaires (8). The ID MigraineTM
self-administered screening instrument, which consists
of only three items, is a validated and reliable tool,
recommended as a simple method for diagnosing
migraine in primary care settings (9). No such validated
tool exists in French.
The objective of this study was to develop, in French,
a short and practical migraine screening tool based on
the ID MigraineTM screen. If validated, such a screening
tool will be useful to estimate the prevalence of migraine
in French-speaking populations and to identify MA.
Methods
Study population
The Nutrition, Environment and Cardiovascular
Health (NESCaV) survey was a cross-sectional popula-
tion-based survey of cardiovascular risk factors con-
ducted between May 2010 and March 2012 in the
province of Lie`ge (Wallonia, Belgium) on a sample of
1017 presumably healthy subjects. The sample was stra-
tiﬁed by gender, age (classiﬁed in ﬁve-year categories)
and district of residence (Lie`ge, Huy, Waremme, and
Verviers). Pregnant women, people living in institu-
tions, and individuals outside the age range of 20–69
years were excluded (10). The protocol of the NESCaV
study was approved by the ethics committee of
the Faculty of Medicine of Lie`ge University
(B70720097541). Most participants (n¼ 751) of the
NESCaV survey ﬁlled in the new migraine-
screening tool but only 67 (8.9%) of them were diag-
nosed with migraine (with or without aura) by the
neurologist (J.S.) depending on his availability in the
hospital. These 67 subjects constituted the study mater-
ial. The clinical diagnosis of migraine was made accord-
ing to the criteria of ICHD-II (7) and was considered as
the gold standard hereafter. The use of the ID
MigraineTM screen was authorized by its author, R.
Lipton.
Design of the questionnaire
The French version of the new screening tool was based
on the ID MigraineTM screen developed and validated
in the United States (US) by Lipton et al. in 2003 (9). In
primary care settings, the ID MigraineTM had a diag-
nostic sensitivity and speciﬁcity of 81% and 75%,
respectively. Its positive predictive value (PPV)
amounts to 93% for the clinical diagnosis of ICHD-I
migraine (9). The three items of the screen record the
presence or absence within the last three months of a
disabling headache (inability to work, study, or do
what you need to do for at least one day) accompanied
by photophobia and nausea (9,11).
The new tool was designed to screen for one-year
prevalence of migraine. The ﬁrst question on disabling
headaches was modiﬁed to focus on the last 12 months
(see Table 1) in order to capture subjects with only a
few attacks a year. The two other questions related to
nausea (or vomiting) and photophobia remained
unchanged. Since MA is a known risk factor for
stroke and associated with cardiovascular diseases
(2,12,13), one question (4(a) and 4(b)) was added to
the ID MigraineTM screen exploring the presence of
visual auras in all or in some attacks; this would
allow identifying MA and ‘‘pure’’ MA. The modiﬁed
‘‘French version’’ of the ID MigraineTM screener is dis-
played in Table 1.
Subjects who answered ‘‘yes’’ to question 1 were
classiﬁed as ‘‘headache suﬀerers.’’ Those who answered
‘‘no’’ constituted the control group. Further headache
suﬀerers were classiﬁed as having migraine (migrain-
eurs) if they answered ‘‘yes’’ for nausea/vomiting (ques-
tion 2) and/or photophobia (question 3) and/or visual
disturbances before headache (question 4). Migraineurs
were classiﬁed as having MA if they responded posi-
tively to visual disturbances before headache.
Statistics
Results for demographic characteristics were expressed
as counts and percentages for categorical variables. The
Chi-square goodness-of-ﬁt test was used to compare the
characteristics of the study subsample and the NESCaV
population. To compare the responses of the 67 study
subjects with those of the NESCaV participants who
ﬁlled in the new migraine screening questionnaire but
were not seen by the neurologist, the classical Chi-
square test was applied. The prevalence of migraine
was estimated with 95% conﬁdence interval (95% CI)
and its relation with age, gender, educational level and
perception of ﬁnancial resources was tested by logistic
regression analysis. Sensitivity, speciﬁcity, PPV and
negative predictive values (NPV) of the screening tool
were calculated with 95% CI, according to the diagno-
sis based on ICHD-II criteria. Cohen kappa coeﬃcient
with 95% CI was used to assess the degree of concord-
ance between the screen and the gold standard. The
signiﬁcance level was set at p< 0.05. All calculations
were performed with the SAS statistical package (ver-
sion 9.3 for Windows).
Results
Subjects
The demographic characteristics of the study subjects
and of the NESCaV population are summarized in
Table 2. The study sample (n¼ 67) consisted of 39
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(58.2%) women and 28 (41.8%) men in the range of 20–
69 years. Thirty-six (53.7%) patients had a high level of
education (university and non-university degree). The
majority of subjects (78.8%) reported having no ﬁnan-
cial diﬃculties. The study sample and the NESCaV
population were comparable in terms of age, gender,
level of education and perception of ﬁnancial resources.
New migraine screening questionnaire
The responses of the NESCaV participants who ﬁlled in
the new migraine screening questionnaire and of the 67
study subjects are summarized in Table 3. No signiﬁ-
cant diﬀerences were seen between the two groups.
Validity of the screening tool
The neurologist diagnosed migraine in 24 of the 67
subjects, yielding a prevalence of 35.8% (95% CI:
24.3–47.3). Prevalence did not diﬀer between women
and men (38.5% vs. 32.1%, p¼ 0.80) and was not
related to age (p¼ 0.17). Among the 24 migraine suf-
ferers, six (four women and two men) had MA, leading
to a prevalence of 9.0% (95% CI: 2.1–15.8).
When considering the new screening tool, 21 subjects
were classiﬁed as having migraine, giving a prevalence
of 31.3% (95%CI: 20.2–42.5). Cohen kappa coeﬃcient
was equal to 0.90 (95% CI: 0.79–1.0), indicating an
excellent agreement between the new screening tool
and the gold standard. The prevalence did not diﬀer
between women and men (38.5% vs. 21.4%, p¼ 0.22)
and was unrelated to age (p¼ 0.18). Seven subjects
(three men and four women) were identiﬁed as MA,
yielding an overall prevalence of 10.4% (95% CI:
3.1–17.8). Cohen kappa coeﬃcient was equal to 0.74
(95% CI: 0.47–1.0).
No association was found between migraine preva-
lence, whether diagnosed by the neurologist or the
screening tool, and level of education or perception of
ﬁnancial resources.
Table 4 displays the diagnostic eﬃcacy of the screen-
ing tool. Sensitivity was 87.5% and speciﬁcity 100%,
yielding a global accuracy level of 95.5%. The PPV was
100% and the NPV was 93.5%.
For MA, sensitivity was 83.3% and speciﬁcity
96.7% with a PPV and an NPV of 71.4% and 98.3%,
respectively.
Discussion
The present study was designed to validate an extended
French version of the ID MigraineTM (or ‘‘ef-ID
Migraine’’) screen self-administered questionnaire.
The new migraine-screening tool was also intended to
Table 1. The modified ‘‘French version’’ of the ID MigraineTM screener (with English translation).
1. Est-ce que dans les 12 derniers mois vous avez eu des
maux de teˆte qui vous ont empeˆche´ de fonctionner
normalement?
1. During the last 12 months, did you have any headaches
that prevented you from functioning normally in your daily
activities?
« oui « yes
« non ! Merci, vous avez termine´ de re´pondre au
questionnaire
« no ! Thank, you have finished the questionnaire
2. Est-ce que ces maux de teˆte se sont accompagne´s de
nause´es (ou de vomissements)?
2. Along with these headaches did you suffer from nausea
(or vomiting)?
« oui « yes
« non « no
3. Est-ce que ces maux de teˆte se sont accompagne´s d’une
sensibilite´ exage´re´e a` la lumie`re (soleil, ne´ons,. . .)?
3. Along with these headaches did you suffer from
exaggerated sensitivity to light (sunlight, neon. . .)?
« oui « yes
« non « no
4a. Est-ce que ces maux de teˆte ont e´te´ pre´ce´de´s juste avant
d’apparaıˆtre par des troubles de la vue (e´clairs, flashs,
taˆches fonce´es, vibrations,. . .)?
4a. Just before these headaches, did you have any visual
disturbances (flashes, dark spots, vibrations. . .)?
« oui « yes
« non « no
4b. Si oui: 4b. If yes:
« chaque fois? « every time?
« pas chaque fois? « not every time?
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be used by general practitioners in the primary care
setting and in epidemiological studies by researchers.
General practitioners and researchers may indeed not
be familiar with the detailed criteria of ICHD-II which
could advantageously be replaced by this novel quick,
easy to use and inexpensive screening instrument.
The ef-ID Migraine is a valid screening tool for
migraine with a high degree of agreement between
Table 2. Demographic characteristics of the study sample and of the Nutrition, Environment and





Characteristic Number (%) Number (%) p value
Age class 0.61
20–24 11 (16.4) 102 (10.0)
25–29 7 (10.4) 98 (9.64)
30–34 7 (10.4) 97 (9.54)
35–39 5 (7.46) 109 (10.7)
40–44 7 (10.4) 114 (11.2)
45–49 11(16.4) 116 (11.4)
50–54 4 (5.97) 113 (11.1)
55–59 6 (8.96) 105 (10.3)
60–64 6 (8.96) 96 (9.44)
65–69 3 (4.48) 67 (6.59)
Gender 0.18
Male 28 (41.8) 506 (49.9)
Female 39 (58.2) 511 (50.1)
Level of education 0.30
Primary—lower secondary 11 (16.4) 204 (20.4)
Non-general upper secondary 8 (11.9) 216 (21.5)
General upper secondary 10 (14.9) 122 (12.1)
Non-university degree 21 (31.3) 263 (26.0)
University degree 15 (22.4) 200 (19.9)
Perception of financial resources 0.70
In need 14 (21.2) 235 (23.2)
Well off 52 (78.8) 778 (76.8)
Table 4. Validity of the new migraine screening tool.
Migraine MA
Sensitivity % (n) 87.5 (21/24) 83.3 (5/6)
95% CI (74.3–100) (53.5–100)
Specificity % (n) 100 (43/43) 96.7 (59/61)
95% CI (91.4–100) (92.3–100)
PPV % (n) 100 (21/21) 71.4 (5/7)
95% CI (82.4–100) (38.0–100)
NPV % (n) 93.5 (43/46) 98.3 (59/60)
95% CI (86.3–100) (95.1–100)
Cohen kappa 0.90 0.74
95% CI (0.79–1) (0.47–1)
CI: confidence interval; PPV: positive predictive value; NPV: negative
predictive value; MA: migraine with aura.
Table 3. Distribution of answers to the new migraine screening
questionnaire for study subjects and Nutrition, Environment and
Cardiovascular Health (NESCaV) survey participants who filled in






Question Yes/no Yes/no p value
1 26/41 266/418 0.99
2 9/17 87/179 0.84
3 19/7 141/125 0.05
4a 7/19 72/194 0.99
4b 6/1 54/17 0.56
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self-reported migraine and migraine diagnosed by a
neurologist. Since we found a high degree of agreement
(14) between reported and clinically diagnosed
migraine, ef-ID Migraine can be used to estimate the
prevalence of migraine. It is a screening tool, not a
diagnostic instrument, because of the rather high
false-negative rate of 12.5%. Because the ﬁrst question
helps identify subjects with disabling headaches in the
last year, the tool selects subjects with active migraine,
which somewhat reduces its sensitivity but increases
speciﬁcity. Concordantly false positives were absent in
our survey for migraine without aura. The ﬁrst three
items of ef-ID Migraine about headache disability,
nausea and photophobia are similar to those of the
English ID MigraineTM. General practitioners and
researchers could use them as a fast and eﬀective instru-
ment for screening migraine.
Compared to the original ID MigraineTM validation
study (9) and other studies of validation of this ques-
tionnaire in other languages, e.g. Italian, Portuguese
and Turkish (15–17), the performance of ef-ID
Migraine in our study was similar with comparable sen-
sitivity but higher speciﬁcity. The observed diﬀerences
in performance between studies can result from the
study design. The validation study of the original ID
MigraineTM used the ﬁrst edition of the International
Classiﬁcation of Headache Disorders (ICHD-I) as
the gold standard (9). In our study, we used ICHD-II
as the gold standard, but this should not markedly
impact the results, as the diagnostic criteria for
migraine are identical between the two editions.
Moreover, these validation studies were conducted
with patients referred to specialized headache centers
(9,15,16), while in our study we used a sample of sup-
posedly healthy subjects from the general population.
Testing a clinical sample of headache patients could
bias the results toward a better performance of the
migraine-screening tool.
Recently, a new migraine-screening questionnaire
intended to be used in clinical practice and research
in the general population, the Migraine Screen
Questionnaire (MS-Q), has shown excellent eﬃcacy,
with sensitivity, speciﬁcity, PPV and NPV all greater
than 80.0%. The tool consists of ﬁve items: frequency
and intensity of headache, duration (between four
hours and three days), nausea, sensitivity to light/
noise, and disability. Unfortunately, the development
and validation of the instrument was not conducted
on a general population sample and it might therefore
not be easily generalized (18).
Many other questionnaires for screening migraine
exist. However, it is important to keep in mind that
an instrument must be chosen with caution depending
on the desired performance and objectives of the
screening (19). Indeed, depending of the setting (spe-
cialty referral settings, general population or primary
care), the requested screening instrument for migraine
may probably need to be adapted. Several studies did
not have optimal expert conﬁrmation of the migraine
diagnosis. Others developed instruments that either had
unfavorable performance characteristics or were too
time consuming for routine use (9,19).
In a recent meta-analysis, MA was found to be an
independent relative risk factor for ischemic stroke,
particularly in women (12). To assess the risk of
stroke, physicians must therefore take MA into account
in patient history. The ef-ID Migraine was developed to
detect MA and could therefore help primary care phys-
icians to integrate this risk factor into stroke risk man-
agement. In our study, the screening of MA had a good
sensitivity and speciﬁcity. This was clearly higher than
the 43% sensitivity and 74% speciﬁcity reported by
Lipton et al. (9). The diﬀerent wording of the question
intended to identify visual auras and the small number
of cases of MA in the current study could explain the
diﬀerence in performance between the two screening
questions.
The study presents some strengths and limitations.
First, it used a representative stratiﬁed sample from the
NESCaV study population (N¼ 1017). Secondly, val-
idation was conducted on a presumably healthy popu-
lation, which limits a possible selection bias. Indeed,
when validations are conducted in specialty referral set-
tings, patients are more likely to be aware of their dis-
ease and concordance likely to be higher.
The ﬁrst question of the ef-ID Migraine screening
tool can be associated with a recall bias. Since the
period of assessment concerns the last 12 months,
some subjects might have forgotten a remote episode
of migraine. The relatively small number of sub-
jects (n¼ 67) represents another limitation of our val-
idation study; however, the responses to the questions
of the ef-ID Migraine did not really diﬀer between the
study subjects (n¼ 67) and the other participants
who completed it (n¼ 684). Moreover, the ef-ID
Migraine did not behave diﬀerently according to age,
gender, educational level and perception of ﬁnancial
resources.
Conclusions
In conclusion, the extended French version of ID
MigraineTM can be seen as a valid and easy-to-use
migraine-screening tool. It is particularly appropriate
for epidemiological studies of migraine prevalence in
French-speaking countries. Further studies are needed
for its validation in primary care settings and for the
validation of the MA screening question.
Streel et al. 441
Clinical implications
. The extended French version of the ID Migraine screen (ef-ID Migraine) can be reliably used to screen
migraine in French-speaking countries.
. The ef-ID Migraine includes a question for screening migraine with aura, which is of clinical importance
because of the strong relation between MA and cardiovascular diseases.
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